Navigation Links
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis
Date:1/15/2009

CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Peptimmune, Inc. ("Peptimmune"), a privately held biotechnology company, announced today that it has granted Novartis (NYSE: NVS) an exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune's multiple sclerosis drug candidate. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Peptimmune.

In the event that Novartis exercises the option to PI-2301, Novartis would assume the global clinical development, manufacturing, and marketing of PI-2301 and all associated costs. Peptimmune would receive payments upon the option exercise and upon successful completion of certain development, regulatory, and commercial milestones. These payments together could total more than $500 million. In addition, Peptimmune shall be eligible to receive royalties on product sales. Additional terms were not disclosed.

"We believe that Novartis represents an outstanding future partner for Peptimmune and the global development of PI-2301. This option agreement provides Peptimmune with access to both Novartis' world class development expertise and the necessary capital to invest in this proprietary product," said Thomas P. Mathers, President and CEO of Peptimmune.

Todd Foley, Managing Director at MPM Capital commented, "Peptimmune and its world-leading expertise in peptide copolymers represent an attractive investment opportunity."

About PI-2301

PI-2301 is a peptide copolymer developed using Peptimmune's novel platform peptide chemistry. PI-2301 is designed to enhance the regulatory response of the immune system, thereby controlling the pathogenic autoimmune response in certain diseases. PI-2301 is currently in Phase 1b development by Peptimmune.

<
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Peptimmune Announces the Second Close of Series D Private Financing
2. Tufts receives NIH grant to study obesity prevention in new immigrants
3. Floridas Uninsured and Underinsured to Benefit from Statewide Grants
4. Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008
5. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
6. The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative
7. Life Sciences Discovery awards health research program grants
8. Blue Cross Foundation Awards $660,000 in Grants to Improve Community Health
9. FDA Grants NeoVistas Request to Utilize Novel Wet AMD Treatment in Compassionate Case
10. UnitedHealth Group Grants to Help Students and Educators Combat Childhood Obesity
11. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... DC (PRWEB) August 20, 2014 Hope ... Heart, Give Hope® Celebration to be hosted in Washington, ... and Navy Club. This signature event honors the courage ... families of the fallen. Proceeds from the Got Heart, ... a national nonprofit dedicated to restoring a sense of ...
(Date:8/20/2014)... Building on growing success by applying ... iii and iv pressure ulcers with extremely high ... A company spokesperson commented that these accuracy levels ... settings. The resulting capabilities can be extended to ... to help providers avoid financial losses while improving ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sodium Chloride IV . , ... of Sodium Chloride IV 0.9%, USP 1000 mL, by Baxter ... of particulate matter. Sodium Chloride Injection, USP is used as ... solution in hemodialysis procedures. , The reason for ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 At this ... of Africa. To help eliminate the root cause of the ... recently teamed up with the nonprofit organization Books For Africa ... Africans: How Every African Can Live the Life of Their ... , This book equips Africans with the tools they need ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3
... broader, patient-centered treatment choices to those ... dealing with substance use disorders, WASHINGTON, ... awarded a $7 million contract to provide technical,assistance to the ... Mental Health Services Administration (SAMHSA) within,the U.S. Department of Health ...
... Serious subject for the funnies becomes basis for Lisa,s Legacy ... in a comic strip,Funky Winkerbean creator Tom Batiuk has depicted ... of breast cancer. Lisa Moore, a major,character who is battling ... Oct. 4, 2007, leaving behind her husband, Les, and their,five-year-old ...
... 2, 2007 Phylonix Pharmaceuticals, Inc. today announced that it ... Grant (SBIR) from the National Eye Institute of the National ... for drug screening. The grant for New Models for ... of three years., The eye is a highly conserved organ ...
... Paramed Systems announced today,the release of their Mobility Offers ... fire, emergency medical, and,rehabilitating patients safely and easily both ... a button. Paramed developed the dual-track MOV in ... capable of safe stairway ascents and,descents. The MOV has ...
... a Full-featured Solution for Home ... DALLAS, Oct. 2 Today, Dynamic Energy Systems, Inc.,(DES) ... on- demand, on-line software solution. The online version,provides access ... so excited to offer our customers a choice when ...
... the Modernization, of its Health Information System Based on BEA ... ... (Assistance Publique - Hopitaux de Marseille) has chosen BEA ... Integration offers an interoperability platform upon which AP-HM has built ...
Cached Medicine News:Health News:Altarum Wins $7 Million Contract to Provide Technical Assistance to the Access to Recovery Program 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 3Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 4Health News:NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 3Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 4Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 5
(Date:8/19/2014)... LOUIS , Aug. 19, 2014  Sequence, Inc., an ... for pharmaceutical, biotech and medical device manufacturers is opening a ... St. Louis , as a result of demand ... new location, which opened this month, allows Sequence to better ... Establishing a St. Louis office provides ...
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 /PRNewswire/ ... announced today a protocol amendment to allow for expanded dosing ... U.S. Food and Drug Administration (FDA) and that a new ... at three clinical trial sites in the United ... of US$2.9 million have been raised through warrant exercise in ...
(Date:8/19/2014)... , August 19, 2014 According ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and ... Growth, Trends and Forecast, 2014 - 2020", the global ... million in 2013 and is expected to grow at ... reach an estimated value of USD 295.5 million in ...
Breaking Medicine Technology:Quality and Compliance Solutions Provider Announces Opening of St. Louis, Missouri Office 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 2Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 3Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 4Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 5Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 6Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 7Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 8Global Surgical Navigation Systems Market to Reach USD 295.5 Million in 2020 - Report by MarketResearchReports.biz 9
... BEIJING, Nov. 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... biopharmaceutical products in China, announced today the positive top-line ... proprietary inactivated vaccine against human enterovirus 71 (EV71), which ... Phase II results for the EV71 vaccine showed a ...
... HARBIN, China, Nov. 9, 2011 /PRNewswire-Asia/ -- China Sky One ... CSKI ), a leading fully integrated pharmaceutical company producing ... announced financial results for the third quarter of 2011. ... Financial Highlights , Total revenues decreased 26.6% year-over-year to ...
Cached Medicine Technology:Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 2Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 3Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease 4China Sky One Medical Announces Third Quarter 2011 Results 2China Sky One Medical Announces Third Quarter 2011 Results 3China Sky One Medical Announces Third Quarter 2011 Results 4China Sky One Medical Announces Third Quarter 2011 Results 5China Sky One Medical Announces Third Quarter 2011 Results 6China Sky One Medical Announces Third Quarter 2011 Results 7China Sky One Medical Announces Third Quarter 2011 Results 8China Sky One Medical Announces Third Quarter 2011 Results 9China Sky One Medical Announces Third Quarter 2011 Results 10China Sky One Medical Announces Third Quarter 2011 Results 11China Sky One Medical Announces Third Quarter 2011 Results 12China Sky One Medical Announces Third Quarter 2011 Results 13China Sky One Medical Announces Third Quarter 2011 Results 14China Sky One Medical Announces Third Quarter 2011 Results 15China Sky One Medical Announces Third Quarter 2011 Results 16China Sky One Medical Announces Third Quarter 2011 Results 17China Sky One Medical Announces Third Quarter 2011 Results 18
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... of cardiology catheters. Available in both Softouch ... with excellent torque, new wire-braid technology for ... large inner lumens for excellent flow rates. ... French sizes with pressure ratings up to ...
Medicine Products: